Crude oil prices fell again after the Energy Information Administration forecast higher crude oil production in the U.S. in 2018. The markets closed mixed with the Dow falling 31 points to 19,855 while Nasdaq gained 20 points to 5,551.
On the upside
Biocept (Nasdaq: BIOC) secured an in-network provider agreement with Blue Cross Blue Shield of Texas.
Signal Genetics (Nasdaq: SGNL) will hold a special shareholder meeting on February 10, 2017 to vote on matters related to the company's proposed merger with Miragen Therapeutics and the sale of Signal's MyPRS intellectual property assets.
xG Technology (Nasdaq: XGTI) regained compliance with Nasdaq listing requirements.
On the downside
NanoString Technologies (Nasdaq: NSTG) reported preliminary full year revenue that fell short of expectations.
DryShips (Nasdaq: DRYS) exercised its option to acquire one Very Large Gas Carrier for $83.5 million.
Halozyme Therapeutics (Nasdaq: HALO) provided program updates and its 2017 financial guidance at the 35th annual JP Morgan Healthcare Conference.
In the broad market, advancing issues outpaced decliners by a margin of more than 5 to 3 on both the NYSE and on Nasdaq. The broader S&P 500 index held steady at 2,268. Bitcoin rose $11 to $890
